Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
University of California, San Francisco · with University of Melbourne · NCT05606237
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 8–13 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- July 14, 2023
- Record last updated
- January 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.
Being studied: Low-level Red Light Therapy Device
Conditions: Myopia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Provision of consent
- Non-Chinese Ethnicity
- Age: ≥8 and ≤13 years at enrollment
- Myopia: Spherical equivalent refractions (SERs) under cycloplegia: -1.00 to -5.00 diopters (D)
- Astigmatism of 2.50 D or less 5) Anisometropia of 1.50 D or less 6) Corrected monocular logMAR visual acuity (VA): 1.0 or better 7) Consent to participate in random allocation of grouping 8) Fluent in English 9) Willing and able to participate in all required activities of the study6) Corrected monocular logMAR visual acuity (VA): 1.0 or better
Exclusion Criteria
- Strabismus and binocular vision abnormalities in either eye
- Ocular abnormalities in either eye or other systemic abnormalities that affect participate in all required activities of the study.
- Other reasons, including but not limited to severe physical and cognitive disability, that the physician may consider inappropriate for enrollment
- Noncompliance with treatment
- Children whose parents do not sign informed consent
Recruiting US locations
University of California, San Francisco
San Francisco, CA 94143
Site contact: Jenny Lu · 415-476-5321 · jenny.lu@ucsf.edu
Study contacts (from the official record)
- Tiffany Chen, MD · 4155143503 · Tiffany.A.Chen@ucsf.edu
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55